|Videos|November 3, 2022
Systemic Therapy in the Treatment of Non-Clear Cell RCC: The Evolving Landscape
Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.
Advertisement
Episodes in this series
Advertisement
Related to this article
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5